Literature DB >> 23995754

Liquid chromatography-tandem mass spectrometry method as the golden standard for therapeutic drug monitoring in renal transplant.

Filippo Aucella1, Vincenzo Lauriola, Gennaro Vecchione, Giovanni Luca Tiscia, Elvira Grandone.   

Abstract

Kidney transplanted patients need immunosuppressant therapies. Therapeutic drug monitoring approaches produce the optimal clinical outcome is still under debate. This review details strength and limits of methods available: immunoassay and chromatography-based. Liquid chromatography with mass spectrometry detection is a major breakthrough in therapeutic drug monitoring of immunosuppressive agents and is considered as the method of choice in therapeutic drug monitoring (TDM) of immunosuppressants. Despite the initial high cost for the instrumentation, HPLC-MS is more cost effective than microparticle enzyme immunoassay. The main important features of LC-MS/MS methodology for immunosuppressive drugs are the shortened analysis time, an increased throughput, higher selectivity, specificity, and sensitivity, and low cost of analysis.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immunosuppression; Kidney transplantation; Liquid chromatography; Mass spectrometry; Therapeutic drug monitoring

Mesh:

Substances:

Year:  2013        PMID: 23995754     DOI: 10.1016/j.jpba.2013.08.001

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  Analyte recovery in LC-MS/MS bioanalysis: An old issue revisited.

Authors:  Devendra Kumar; Nagsen Gautam; Yazen Alnouti
Journal:  Anal Chim Acta       Date:  2022-01-28       Impact factor: 6.558

Review 2.  Review of Chromatographic Methods Coupled with Modern Detection Techniques Applied in the Therapeutic Drugs Monitoring (TDM).

Authors:  Tomasz Tuzimski; Anna Petruczynik
Journal:  Molecules       Date:  2020-09-03       Impact factor: 4.411

3.  UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.

Authors:  Joachim Kuhn; Tatjana Gripp; Tobias Flieder; Marcus Dittrich; Doris Hendig; Jessica Busse; Cornelius Knabbe; Ingvild Birschmann
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.